BNP Paribas Financial Markets Invests $461,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

BNP Paribas Financial Markets acquired a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 60,079 shares of the company's stock, valued at approximately $461,000. BNP Paribas Financial Markets owned 0.16% of iTeos Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Empowered Funds LLC raised its stake in iTeos Therapeutics by 5.0% in the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock valued at $530,000 after purchasing an additional 3,305 shares in the last quarter. Virtu Financial LLC increased its holdings in iTeos Therapeutics by 84.3% in the 4th quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock valued at $142,000 after buying an additional 8,460 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of iTeos Therapeutics in the 4th quarter valued at approximately $142,000. US Bancorp DE raised its position in shares of iTeos Therapeutics by 40.1% in the 4th quarter. US Bancorp DE now owns 16,919 shares of the company's stock valued at $130,000 after buying an additional 4,843 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of iTeos Therapeutics during the 4th quarter worth approximately $1,159,000. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Price Performance

ITOS stock traded down $0.03 during midday trading on Thursday, reaching $10.03. 3,770,303 shares of the stock were exchanged, compared to its average volume of 637,758. iTeos Therapeutics, Inc. has a 52 week low of $4.80 and a 52 week high of $18.13. The company has a fifty day moving average price of $6.92 and a 200 day moving average price of $7.40. The stock has a market capitalization of $383.89 million, a PE ratio of -3.18 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. As a group, analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other iTeos Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of iTeos Therapeutics stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the transaction, the insider now directly owns 2,108,594 shares of the company's stock, valued at approximately $16,995,267.64. The trade was a 23.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $8,317,363.86. Following the completion of the sale, the insider now directly owns 3,452,797 shares of the company's stock, valued at approximately $27,829,543.82. The trade was a 23.01% decrease in their position. The disclosure for this sale can be found here. 12.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ITOS shares. Piper Sandler reissued an "overweight" rating and issued a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Raymond James set a $12.00 price target on iTeos Therapeutics in a research note on Wednesday, May 14th. HC Wainwright downgraded iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Wedbush lowered iTeos Therapeutics from an "outperform" rating to a "neutral" rating and raised their price objective for the company from $10.00 to $12.00 in a research note on Wednesday. Finally, Leerink Partnrs cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, iTeos Therapeutics currently has an average rating of "Hold" and an average target price of $15.86.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.